Basic Information
ID DDInter2227
Drug Type small molecule
Molecular Formula C24H30N8O
Molecular Weight 446.559
CAS Number 1374743-00-6
Description Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.[A229313] Trilaciclib was granted FDA approval on 12 February 2021.[L31823]
ATC Classification V03AF12
IUPAC Name 12'-{[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino}-2',5',11',13'-tetraazaspiro[cyclohexane-1,3'-tricyclo[7.4.0.0^{2,7}]tridecane]-1'(9'),7',10',12'-tetraen-6'-one
InChI PDGKHKMBHVFCMG-UHFFFAOYSA-N
Canonical SMILES CN1CCN(CC1)C1=CN=C(NC2=NC3=C(C=C4N3C3(CCCCC3)CNC4=O)C=N2)C=C1
Useful Links DrugBank ChemSpider BindingDB Wikipedia ChEMBL
Interactions with Trilaciclib
Filter:
Severity level ID Name Mechanism Detail
Interactions with diseases
Filter:
Severity level Disease name Text References
Interactions with foods
Filter:
Severity level Food name Description Management Mechanism References
Interactions with compound preparation
Multi-DRUG trade Multi-DRUG Drug type Warning Note